Abstract:Aberrant tumor metabolic activities not only promote the aggressiveness and proliferation of tumor cells in the harsh microenvironment in vivo, but also contribute to immune cell dysfunction and immunosuppressive TME. This phenomenon poses a major challenge to cancer immunotherapy. Thus, tumor metabolic interventions might be a promising strategy to reverse immune suppression for boosting anti-tumor immunotherapy. Herein, biomimetic multifunctional nanodrugs (CM-ZIF8@Ce6/Lon) were constructed for collaborative tumor metabolic regulation and photodynamic (PDT) amplified immunotherapy. These nanodrugs were prepared by homotypic tumor cell membrane (CM)-camouflaged zeolitic imidazolate framework-8 (ZIF-8) nanoparticles embedded with photosensitizer (Chlorin e6, Ce6) and metabolic modulator (Lonidamine, Lon). We carried out a series of experiments to explore the possible mechanism of CM-ZIF8@Ce6/Lon for tumor metabolic regulation. Firstly, CM-ZIF8@Ce6/Lon could actively metastasis towards tumor cells based on the homotypic targeting property. Subsequently, the nanodrugs blocked tumor metabolic pathways and reduced metabolites accumulation, therefore reversing the immunosuppressive TME through releasing Lon. Meanwhile, the released Ce6 from these nanodrugs triggered PDT efficiency on the tumor suppression, and induced ICD effect to activate the cascade immune response. The regulation of tumor metabolism disorders synergistically augmented PDT-mediated immunotherapy through reduction of regulatory T cells, enhancement of CD8+ T cell infiltration and upregulation of inflammatory factors. As a result, CM-ZIF8@Ce6/Lon efficiently inhibited the primary and metastatic tumor. Overall, our study explored mechanism of tumor metabolic regulation to reverse the immunosuppressive TME and demonstrated the important potential of the synergistic anti-tumor. This multifunctional nanodrug may provide new insight for developing a promising therapeutic tool to reverse immunosuppression and boost anti-tumor immunotherapy.

Reversing the negative effect of adenosine A1 receptor-targeted immunometabolism modulation on melanoma by a co-delivery nanomedicine for self-activation of anti-PD-L1 DNAzyme

Bimetallic Peroxide-Based Nanotherapeutics for Immunometabolic Intervention and Induction of Immunogenic Cell Death to Augment Cancer Immunotherapy

Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor.

Near‐Infrared Responsive Membrane Nanovesicles Amplify Homologous Targeting Delivery of Anti‐PD Immunotherapy Against Metastatic Tumors

Inspired Epigenetic Modulation Synergy with Adenosine Inhibition Elicits Pyroptosis and Potentiates Cancer Immunotherapy

Biomimetic multifunctional nanodrugs enable regulating abnormal tumor metabolism and amplifying PDT-induced immunotherapy for synergistically enhanced tumor ablation

Suppressing the Hypoxia‐Adenosinergic Axis by a Tailored Nanoreactor for Enhanced Photothermal Immunotherapy

Amplified antitumor efficacy by a targeted drug retention and chemosensitization strategy-based “combo” nanoagent together with PD-L1 blockade in reversing multidrug resistance

Dendritic Polymer-Functionalized Nanomedicine Potentiates Immunotherapy Via Lethal Energy Crisis-Induced PD-L1 Degradation.

Photothermal nanobomb blocking metabolic adenosine-A2AR potentiates infiltration and activity of T cells for robust antitumor immunotherapy

Nanotechnology-mediated Immunochemotherapy Combined with Docetaxel and PD-L1 Antibody Increase Therapeutic Effects and Decrease Systemic Toxicity.

Long-term combined blockade of CXCR4 and PD-L1 with in vivo reassembly for intensive tumor interference

Reducing PD-L1 Expression with a Self-Assembled Nanodrug: an Alternative to PD-L1 Antibody for Enhanced Chemo-Immunotherapy.

A Smart Nanomedicine Unleashes a Dual Assault of Glucose Starvation and Cuproptosis to Supercharge Αpd-L1 Therapy.

A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD-1/PD-L1 Axis.

PD-1/PD-L1 Pathway and Angiogenesis Dual Recognizable Nanoparticles for Enhancing Chemotherapy of Malignant Cancer

Genetically engineered nanovesicles mobilize synergistic antitumor immunity by ADAR1 silence and PDL1 blockade

Engineering Chameleon Prodrug Nanovesicles to Increase Antigen Presentation and Inhibit PD‐L1 Expression for Circumventing Immune Resistance of Cancer

Potentiating dual-directional immunometabolic regulation with nanomedicine to enhance anti-tumor immunotherapy following incomplete photothermal ablation

Boosting Cancer Immunotherapy Via Reversing PD-L1-Mediated Immunosuppression with a Molecularly Imprinted Lysosomal Nanodegrader

Photothermal Therapy Mediated by Phase-Transformation Nanoparticles Facilitates Delivery of Anti-Pd1 Antibody and Synergizes with Antitumor Immunotherapy for Melanoma